Comparative Pharmacology
Head-to-head clinical analysis: ANAPROX DS versus CHILDREN S ADVIL FLAVORED.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANAPROX DS versus CHILDREN S ADVIL FLAVORED.
ANAPROX DS vs CHILDREN'S ADVIL-FLAVORED
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Naproxen is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis.
Ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis, resulting in antipyretic, analgesic, and anti-inflammatory effects.
550 mg orally every 8 to 12 hours; maximum 1375 mg/day.
200-400 mg orally every 4-6 hours as needed; maximum 1200 mg/day without prescription, up to 3200 mg/day under medical supervision.
None Documented
None Documented
Terminal elimination half-life is approximately 12–17 hours (mean ~14 hours), allowing twice-daily dosing. Steady-state is achieved after 4–5 doses.
2-4 hours in children; prolonged in neonates (up to 30 hours) and hepatic impairment.
Renal elimination of naproxen and its metabolites accounts for approximately 95% of the dose, with about 60% as unchanged drug and 40% as conjugated or hydroxylated metabolites. Biliary/fecal excretion is negligible (<5%).
Renal excretion of conjugated metabolites (75-80% as glucuronide and sulfate conjugates, <10% as unchanged drug); biliary/fecal elimination accounts for <5%.
Category C
Category C
NSAID
NSAID